Senior executive with experience in strategic finance and corporate development across healthcare and consumer sectors, often focused on transaction execution, performance improvement and investor relations. Marina Angela Medley De brings cross-functional leadership from operating and advisory roles, engaging capital partners, overseeing M&A processes and aligning financial strategy with growth initiatives.
Senior executive with experience in strategic finance and corporate development across healthcare and consumer sectors, often focused on transaction execution, performance improvement and investor relations. Marina Angela Medley De brings cross-functional leadership from operating and advisory roles, engaging capital partners, overseeing M&A processes and aligning financial strategy with growth initiatives.
Prioritizes disciplined, transaction-focused capital allocation that leverages strategic finance and corporate development experience to drive value in healthcare and consumer businesses. Emphasizes diligenced M&A and partnership sourcing, active portfolio performance improvement, and alignment of capital structure with growth initiatives. Favors mid‑cycle opportunities where operational fixes and strategic repositioning unlock upside, applies rigorous investor-relations discipline to manage exit timing, and balances growth orientation with measurable cash‑flow and execution risk controls.
Prioritizes disciplined, transaction-focused capital allocation that leverages strategic finance and corporate development experience to drive value in healthcare and consumer businesses. Emphasizes diligenced M&A and partnership sourcing, active portfolio performance improvement, and alignment of capital structure with growth initiatives. Favors mid‑cycle opportunities where operational fixes and strategic repositioning unlock upside, applies rigorous investor-relations discipline to manage exit timing, and balances growth orientation with measurable cash‑flow and execution risk controls.
| Trades 10 | Longs Won 3/10 30% | Profit Factor 0.05 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $27.76M |
| Average Win $1.68M | Best Trade (Sep 30) $4.72M | Sharpe Ratio -9.6 |
| Average Loss -$14.92M | Worst Trade (Oct 14) -$87.96M | Z-Score 0.25 (19.39%) |
| Commissions $0 | Avg. Trade Length 5m 1w 6d | Expectancy -$9.94M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 10 | 9 | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AOR iShares Core 60/40 Balanced Allocation ETF | 6,470 | $449,665 | $445,006.6 | - | -$4,658.4 | -1.04% | +0.044% |
ARTY iShares Future AI & Tech ETF | 20,319 | $1.59M | $1.57M | - | -$23,773.15 | -1.49% | -0.349% |
PSKY Paramount Skydance Corporation Class B Common Stock | 178,732 | $1.87M | $1.66M | - | -$218,053.04 | -11.63% | +1.201% |
QQQ Invesco QQQ Trust, Series 1 | 611 | $449,940 | $454,321.28 | - | $4,381.28 | 0.97% | -0.331% |
QXO Qxo Inc. | 10.94M | $208.53M | $120.57M | - | -$87.96M | -42.18% | +3.571% |
URTH iShares MSCI World ETF | 110,601 | $22.81M | $23.13M | - | $324,061.16 | 1.42% | +0.11% |